From genome-wide arrays to tailor-made biomarker readout – Progress towards routine analysis of skin sensitizing chemicals with GARD  by Forreryd, Andy et al.
Toxicology in Vitro 37 (2016) 178–188
Contents lists available at ScienceDirect
Toxicology in Vitro
j ourna l homepage: www.e lsev ie r .com/ locate / tox inv i tFrom genome-wide arrays to tailor-made biomarker readout – Progress
towards routine analysis of skin sensitizing chemicals with GARDAndy Forreryd a, Kathrin S. Zeller a, Tim Lindberg a, Henrik Johansson b, Malin Lindstedt a,⁎
a Department of Immunotechnology, Medicon Village (406), 22381 Lund, Sweden
b SenzaGen AB, Medicon Village (406), 22381 Lund, Sweden⁎ Corresponding author at: Lund University, Medico
Sweden.
E-mail addresses: andy.forreryd@immun.lth.se (A. For
kathrin.zeller@immun.lth.se (K.S. Zeller), tim.lindberg@im
henrik.johanson@senzagen.com (H. Johansson), malin.lin
(M. Lindstedt).
http://dx.doi.org/10.1016/j.tiv.2016.09.013
0887-2333/© 2016 The Authors. Published by Elsevier Ltda b s t r a c ta r t i c l e i n f oArticle history:
Received 19 July 2016
Accepted 9 September 2016
Available online 13 September 2016Allergic contact dermatitis (ACD) initiated by chemical sensitizers is an important public health concern. To pre-
vent ACD, it is important to identify chemical allergens to limit the use of such compounds in various products. EU
legislations, as well as increased mechanistic knowledge of skin sensitization have promoted development of
non-animal based approaches for hazard classiﬁcation of chemicals. GARD is an in vitro testing strategy based
on measurements of a genomic biomarker signature. However, current GARD protocols are optimized for iden-
tiﬁcation of predictive biomarker signatures, and not suitable for standardized screening.
This study describes improvements to GARD to progress from biomarker discovery into a reliable and cost-effec-
tive assay for routine testing. Gene expressionmeasurementswere transferred to NanoString nCounter platform,
normalization strategywas adjusted to ﬁt serial arrival of testing substances, and a novel strategy to correct batch
variations was presented. When challenging GARD with 29 compounds, sensitivity, speciﬁcity and accuracy
could be estimated to 94%, 83% and 90%, respectively.
In conclusion, we present a GARD workﬂow with improved sample capacity, retained predictive performance,
and in a format adapted to standardized screening. We propose that GARD is ready to be considered as part of
an integrated testing strategy for skin sensitization.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).Keywords:
GARD
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Skin sensitization1. Introduction
Hallmarks of sensitization to small reactive chemical substances in-
clude activation of dendritic cells (DCs) and initiation of adaptive im-
mune responses. Upon repeated exposure to the same compound,
speciﬁc Th1 and cytotoxic CD8+ T-cells elicit an inﬂammatory reaction
in the skin, resulting in development of clinical symptoms, such as aller-
gic contact dermatitis (ACD) (Akhavan & Cohen, 2003; Fonacier,
Dreskin, & Leung, 2010). Chemical allergens, currently exceeding 4000
known substances (DeGroot, 2008) are present in a variety of products
found in households and atworkplaces. Common examples include fra-
grances, cosmetics (Peiser et al., 2012), and certain vulcanized rubber
products, such as disposable rubber gloves (Bergendorff, Persson,
Ludtke, & Hansson, 2007; Geier, Lessmann, Uter, & Schnuch, 2003).
The incidence of ACD is increasing as a consequence of frequent expo-
sure to these products (Lunder & Kansky, 2000; Nguyen, Dang,n Village (406), 22381 Lund,
reryd),
mun.lth.se (T. Lindberg),
dstedt@immun.lth.se
. This is an open access article underMacPherson, Maibach, & Maibach, 2008). ACD is the most frequent
manifestation of immunotoxicity in humans (Kimber, Basketter,
Gerberick, & Dearman, 2002), affecting approximately 20% of the gener-
al population (Thyssen, Linneberg, Menne, & Johansen, 2007), and is es-
pecially problematic within certain occupational groups, such as health
care workers and cleaners (Dickel, Kuss, Blesius, Schmidt, & Diepgen,
2001).
To limit exposure to hazardous chemical allergens, the European
Union (EU) has enforced legislations such as REACH (EU, 2006), which
requires risk assessment of all chemicals produced N1 ton/year. Identi-
ﬁcation of chemical allergens is routinely performed with animal
models, such as the murine local lymph node assay (LLNA) (Basketter
et al., 2002). Since 2013, animal testing of cosmetic products, or ingredi-
ents thereof is banned within the EU (EU, 2009), and similar initiatives
have been enforced, or are currently under the investigation in several
countries. Such legislations, together with detailed knowledge of key
mechanistic events linked to ACD, summarized in an adverse outcome
pathway (AOP) (OECD, 2012), has challenged the traditional use of
high-dose animal models, resulting in a paradigm shift within the ﬁeld
of toxicity testing, to promote the use of knowledge- and mode of ac-
tion-based testing using in vitromodels.
To this end, all key mechanistic events in the AOP for skin sensitiza-
tion have been targeted for the development of various in vitro, inthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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2015). The direct peptide reactivity assay (DRPA) (Gerberick et al.,
2004), KeratinoSens™ (Natsch, 2010), and the human cell line activa-
tion test (h-CLAT) (Ashikaga et al., 2006; Nukada et al., 2011), have
been validated by European Reference Laboratory for alternatives to an-
imal testing (EURL ECVAM) for use within Integrated Approaches to
Testing and Assessment (IATA). These assays are based on single or
few biomarkers, providing limited mechanistic information. Thus,
there is still a need for reliable assayswith higher informational content,
targeting complementary mechanistic events.
Genomic allergen rapid detection (GARD) (Johansson, Albrekt,
Borrebaeck, & Lindstedt, 2013; Johansson, Lindstedt, Albrekt, &
Borrebaeck, 2011) developed by our group is based on measurements
of transcriptional levels of 200 genomic biomarkers, collectively re-
ferred to as the GARD prediction signature (GPS), in a myeloid cell
line using transcriptome-wide microarray proﬁling. Transcripts in the
GPS are involved in cellular pathways associated with antigen recogni-
tion, DC maturation and cellular stress, thus immunologically relevant
to the sensitization process. Upon cellular stimulationwith an unknown
compound, the induced changes in gene expression levels within the
GPS are compared to proﬁles of reference chemicals using supervised
machine leaning based on support vector machines (SVM) (Cortes &
Vapnik, 1995). In a recent in-house validation study, the accuracy of
GARD was estimated to 89% for classiﬁcation of 26 blinded compounds
(Johansson et al., 2014). However, the microarray platform used for
identiﬁcation of transcripts in GPS is not well-adapted for routine test-
ing of a large number of chemicals, due to limitations in sample
throughput, high costs and complex protocols. Furthermore, several
groups have reported reproducibility issues between experiments per-
formed on the microarray platform (Draghici, Khatri, Eklund, &
Szallasi, 2006; Liang, 2007; Murphy, 2002). Thus, we have evaluated
the performance of three medium-throughput platforms on a subset
of transcripts from the GPS (Forreryd, Johansson, Albrekt, & Lindstedt,
2014), and showed that the NanoString nCounter platform (Geiss et
al., 2008)was a promising ampliﬁcation-free alternative tomicroarrays.
The platform allows for speciﬁc detection of individual transcripts in a
multiplex format with high sample throughput, while providing a re-
source-effective, simple and highly automated protocol with little
hands-on time.
In this study, we present a novel GARD workﬂow to meet industrial
and regulatory demands for reliability, cost effectiveness and sample ca-
pacity. In a ﬁrst step, we transferred the gene expressionmeasurements
from transcriptome-wide proﬁling using microarrays, into the
NanoString nCounter platform, measuring only the transcripts in the
GPS biomarker signature. In a second step to further improve robust-
ness and reliability in classiﬁcations, we modiﬁed the normalization
strategy, evaluated a selection of machine learning algorithms, and in-
troduced a novel approach to adjust for batch variations. As a ﬁnal
proof of concept to validate the novel workﬂow, we performed an in-
house validation study involving the classiﬁcation of 29 independent
test compounds. Based on results in this study, we here present a reli-
able and robust experimental design, establishing the applicability of
the GARD assay for routine screening of skin sensitizing compounds.
2. Material and methods
2.1. Chemicals and datasets
A total of 38 chemical compounds, including 18 well-deﬁned skin
sensitizing compounds and 20 non-sensitizing compounds (Table 1),
as well as the vehicle controls water and dimethyl sulfoxide (DMSO)
were used for stimulation of cells in order to generate the training set
for supervised machine learning and for construction of predictive
models. Compounds were identical to those used during identiﬁcation
of the GARD prediction signature, as described in Johansson, Lindstedt,
Albrekt, & Borrebaeck (2011). In addition to the training set, a total of29 chemical compounds were used for stimulation of cells in order to
generate independent test sets for validation of predictive models
(Table 2). The 29 compounds were further divided into two separate
datasets, referred to as test set 1 and test set 2. Test set 1 comprised a
total of 20 chemical compounds, including 16 compounds previously
classiﬁed in GARD (Johansson et al., 2014). Test set 2 comprised a
total of nine chemical compounds, all previously unseen by the model,
and none of the compounds previously classiﬁed by GARD. In addition,
each test set included a selection of internal control compounds from
the training data set, so-called benchmark control samples. Such com-
pounds included in test set 1 and test set 2 were collectively referred
to as benchmark set 1 (n= 12), and benchmark set 2 (n= 10), respec-
tively (Table 2). All chemical compounds in this study were purchased
from Sigma Aldrich (St. Louis, MO, USA), except the chemicals DMTBS
andDETBS, whichwere a kind gift fromDr. Ola Bergendorff, Dept. of Oc-
cupational and Environmental Dermatology at Lund University,
Sweden.
2.2. Cell handling, chemical stimulations, phenotypic analysis and total RNA
isolation
Each chemical compound was dissolved in appropriate vehicle
(water or DMSO), based on solubility properties, and used for stimula-
tions of cells at a single concentration, called the GARD input concentra-
tion. These concentrations were determined based on cytotoxicity and
solubility of individual compounds, using previously established proto-
cols, as described in Johansson, Albrekt, Borrebaeck, & Lindstedt (2013).
The myeloid cell line MUTZ-3 was purchased from Liebniz-Institut
DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen
(DSMZ, Braunschweig, Germany). All cellular stimulations were per-
formed in triplicate reactions, using a new batch of cells for each indi-
vidual replicate, generating a total dataset comprising 273
stimulations (training set= 120, test set 1=60, test set 2= 27, bench-
mark set 1 = 36, benchmark set 2 = 30). Handling of cells, including
preparation of cells prior to stimulations, quality control of cells, ﬂow
cytometry analysis, and chemical stimulations were performed in ac-
cordance with previously published protocols (Johansson, Lindstedt,
Albrekt, & Borrebaeck, 2011; Johansson, Albrekt, Borrebaeck, &
Lindstedt, 2013). After 24 h of cellular stimulations, cells were harvest-
ed, lysed in TRizol reagent (Thermo Scientiﬁc, Waltham, MA), and
stored at −20°C until RNA extraction. Total RNA was isolated from
TRizol reagent using Direct-zol™ RNA MiniPrep column puriﬁcation
kit (Zymo research, Irvine, CA) according to protocols provided byman-
ufacturer, and concentrations were determined using Agilent
Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA). Total RNA
was stored at−80°C until analysis.
2.3. CodeSet design: selection of probes for endogenous and candidate ref-
erence transcripts
NanoString nCounter probe pairs (NanoString Technologies, Seattle,
WA) targeting endogenous transcripts in the GPS were carefully de-
signed to match at exon level to the transcripts of the Affymetrix
HuGene 1.0 ST array measurements (Johansson, Lindstedt, Albrekt, &
Borrebaeck, 2011). Each probe pair was translated to the 100 bp target
sequence using Affymetrix exon probe set IDs as identiﬁer for a speciﬁc
target exon. In caseswhere several different exonswere possible targets
for probe selection to an individual transcript, design priority was given
to exons giving rise to highest signal on the Affymetrix HuGene 1.0 ST
arraymeasurements, at the same time falling within the kinetic param-
eters of the nCounter system, and not cross-reacting with non-target
transcripts. In total, 196 transcripts could be matched to appropriate
Nanostring probe IDs and included in the custom CodeSet (Supplemen-
tary Table 1). Candidate reference transcripts were selected from the
nCounter human reference GX kit, or selected based on low expression
variance from available Affymetrix HuGene 1.0 ST array measurements
Table 1
Chemical compounds included in the training set.
Compound Abbreviation Chemical abstract service (CAS) Vehicle GARD input concentration (μM)
Skin sensitizers
2,4-Dinitrochlorobenzene DNCB 97-00-7 DMSO 4
2-Aminophenol 2AP 95-55-6 DMSO 100
2-Hydroxyethyl acrylate 2HA 818-61-1 ddH2O 100
2-Mercaptobenzothiazole MBT 149-30-4 DMSO 250
2-Nitro-1,4-phenylenediamine NPDA 5307-14-2 DMSO 300
α-Hexylcinnamic aldehyde HCA 101-86-0 DMSO 32
Cinnamyl alcohol CALD 104-54-1 DMSO 500
Ethylenediamine EDA 107-15-3 ddH2O 500
Eugenol EU 97-53-0 DMSO 300
Formaldehyde solution FA 50-00-0 ddH2O 80
Geraniol GER 106-24-1 DMSO 500
Glyoxal solution GO 107-22-2 ddH2O 300
Isoeugenol IEU 97-54-1 DMSO 300
Kathon CG/ICP KCD –a ddH2O 0.0035%
Penicillin G PEN G 113-98-4 ddH2O 500
Potassium dichromate PD 7778-50-9 ddH2O 1.5
p-Phenylenediamine PPD 106-50-3 DMSO 75
Resorcinol RC 108-46-3 ddH2O 500
Non-sensitizers
1-Butanol BUT 71-36-3 DMSO 500
4-Aminobenzoic acid PABA 150-13-0 DMSO 500
4-Hydroxybenzoic acid HBA 99-96-7 DMSO 250
Benzaldehyde BA 100-52-7 DMSO 250
Chlorobenzene CB 108-90-7 DMSO 98
Diethyl phthalate DP 84-66-2 DMSO 50
Ethyl vanillin EV 121-32-4 DMSO 500
Glycerol GLY 56-81-5 ddH2O 500
Isopropanol IP 67-63-0 ddH2O 500
Lactic acid LA 50-21-5 ddH2O 500
Methyl salicylate MS 119-36-8 DMSO 500
N,N-Dimethylformamide DF 68-12-2 ddH2O 500
Octanoic acid OA 124-07-2 DMSO 500
Phenol PHE 108-95-2 ddH2O 500
Potassium permanganate PP 7722-64-7 DMSO 38
Propylene glycol PG 57-55-6 ddH2O 500
Salicylic acid SA 69-72-7 DMSO 500
Sodium dodecyl sulphate SDS 151-21-3 ddH2O 200
Tween 80 T80 9005-65-6 DMSO 500
Zinc sulphate solution ZS 7733-02-0 ddH2O 126
a Kathon CG is a mixture of the active ingredients 5-chloro-2-methyl-4-isothiazolin-3-one (CAS: 26172-55-4) and 2-methyl-4-isothiazolin-3-one (CAS: 2682-20-4). Kathon is a reg-
istered trademark of Rohm and Hass (Philadelphia, PA, USA).
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dogenous probe pairs and candidate reference probe pairs, and master
kits containing all reagents used to perform gene expression measure-
ments on nCounter, were obtained from NanoString Technologies.
2.4. Gene expression measurements on NanoString nCounter
Gene expression measurements were performed on the NanoString
GEN2 nCounter Analysis System comprising the GEN2 Prep Station 5s
for post-hybridization processing, and the Digital Analyzer 5s for data
collection. All steps were performed according to standardized proto-
cols for gene expression measurements as provided by NanoString.
CodeSet and hybridization buffer were mixed with 100 ng total RNA
(5 μl at 20 ng/μl) and incubated at 65 °C for 24 h. After hybridization,
samples were transferred to the Prep Station and processed using the
High Sensitivity protocol. At conclusion of protocol, cartridges were
sealed with cartridge adhesive cover, transferred to the Digital Analyzer
and matched to the Cartridge Deﬁnition File (CDF). Data collection was
initiated immediately, using maximal data resolution (555 Fields of
view). Data from all runs (n=273)were imported into nSolver version
2.0 (NanoString Technologies), matched to corresponding Reporter Li-
brary File (RLF), and subjected to quality control using the software
quality metrics with default cutoff criteria.2.5. Data pre-processing, selection of reference genes and normalization
Two different normalization methods were applied to the nCounter
data. In the ﬁrst strategy, raw gene expression data was normalized ac-
cording to protocols recommended by NanoString in the nCounter Ex-
pression Data Analysis guide. In short, raw data was adjusted for
platform associated sources of variation using geometrical average of
counts from positive control probes, and non-speciﬁc background was
adjusted by subtracting average counts for negative control probes
(using counts b25 as a threshold for including a speciﬁc negative
probe) in each sample. The geometric mean of reference genes was
used for correction of differences in RNA input between samples. The
best performing reference genes were evaluated from the set of candi-
date reference genes (n = 24, Supplementary Table 2) on samples in
training set. The GeNorm (Vandesompele et al., 2002) and NormFinder
(Andersen, Jensen, & Orntoft, 2004) algorithms were used for rankings.
GeNorm calculationswere performed using an in-housemodiﬁed script
implemented intoR statistical environment version 3.2.4 (RDevelopment
Core Team, 2013), and rankings were based on average stability values
(M) of remaining candidate reference genes during stepwise exclusion
of the least stable gene. NormFinder calculations were performed using
the R script provided by Molecular Diagnostic Laboratory, Dept. of
Molecular Medicine (Aarhus University Hospital Skejby, Denmark), and
Table 2
Chemical compounds included in benchmark sets and independent test sets for validation of GPS.
Compound Abbreviation Class CAS Vehicle GARD input (μM)
Benchmark set 1 and 2
2,4-Dinitrochlorobenzene DNCB Sensitizer 97-00-7 DMSO 4
2-Aminophenol 2AP Sensitizer 95-55-6 DMSO 100
2-Hydroxyethyl acrylate 2HA Sensitizer 818-61-1 ddH2O 100
Geraniol GER Sensitizer 106-24-1 DMSO 500
Isoeugenola IEU Sensitizer 97-54-1 DMSO 300
p-Phenylenediamine PPD Sensitizer 106-50-3 DMSO 75
Resorcinol RC Sensitizer 108-46-3 ddH2O 500
1-Butanol BUT Non-Sensitizer 71-36-3 DMSO 500
Benzaldehydea BA Non-Sensitizer 100-52-7 DMSO 250
Chlorobenzene CB Non-Sensitizer 108-90-7 DMSO 98
Dimethyl sulfoxide DMSO Vehicle control 67-68-5
Double-distilled water ddH2O Vehicle control
Testset 1
2-Nitro-1,4-phenylenediamine NPDA Sensitizer 5307-14-2 DMSO 300
4-Nitrobenzyl bromide 4NBB Sensitizer 100-11-8 DMSO 5
7-Hydroxycitronellal 7HC Sensitizer 107-75-5 DMSO 500
Benzalkonium chlorideb BZK Sensitizer 63449-41-2 DMSO 3
Diethyl maleate DEM Sensitizer 141-05-9 DMSO 200
Diphenylcyclopropenone DPC Sensitizer 886-38-4 DMSO 8
Ethyl acrylate EA Sensitizer 140-88-5 DMSO 500
Hydroquinone HQ Sensitizer 123-31-9 DMSO 45
Lauryl gallate LG Sensitizer 1166-52-5 DMSO 3
Phenylacetaldehyde PA Sensitizer 122-78-1 DMSO 75
Tetramethylthiuram disulﬁde TMTD Sensitizer 137-26-8 DMSO 0.1
Dimethyl isophthalate DMI Non-Sensitizer 1459-93-4 DMSO 250
Hexane HEX Non-Sensitizer 110-54-3 DMSO 500
Lactic acidc LA Non-Sensitizer 50-21-5 ddH2O 500
Menthol MEN Non-Sensitizer 89-78-1 DMSO 500
Methyl salicylatec MS Non-Sensitizer 119-36-8 DMSO 500
Saccharin SAC Non-Sensitizer 81-07-02 DMSO 500
Salicylic acidc SA Non-Sensitizer 69-72-7 DMSO 500
Sodium dodecyl sulphatec,b SDS Non-Sensitizer 151-21-3 ddH2O 500
Xylenes XYL Non-Sensitizer 1330-20-7 DMSO 500
Testset 2
2,4-Dinitroﬂuorobenzene DNFB Sensitizer 70-34-8 DMSO 10
3-Methylcatechol 3MCAT Sensitizer 488-17-5 DMSO 40
Butyl glycidyl ether BGE Sensitizer 2426-08-6 DMSO 500
Diethylthiocarbamyl benzothiazole sulﬁded DETBS Sensitizer 95-30-7 DMSO 30
Dimethylthiocarbamyl benzothiazole sulﬁded DMTBS Sensitizer 3432-25-5 DMSO 8
Lyral LYR Sensitizer 31906-04-4 DMSO 100
1-Bromobutane 1BB Non-Sensitizer 109-65-9 DMSO 500
Benzoic acid BEA Non-Sensitizer 65-85-0 DMSO 500
Citric acid CIA Non-Sensitizer 77-92-9 DMSO 500
a Compounds included only in benchmark control samples for test set 1.
b Compounds are false classiﬁcations in LLNA. Benzalkoniumchloride is a false negative (Haneke, Tice, Carson,Margolin, & Stokes, 2001), and sodiumdodecyl sulphate is a false positive
(Gerberick et al., 2005).
c Compounds also present in the training set.
d Compounds have not been classiﬁed in LLNA. Classiﬁcations are based on positive results in human patch testing (Hansson, Ponten, Svedman, & Bergendorff, 2014).
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between subgroups of samples into considerations by using annotations
for sensitizers and non-sensitizers. In the second normalization strategy,
raw nCounter gene expression data was normalized using an in-house
developed single-sample normalization strategy implemented into R
statistical environment, called Counts per Total Counts (CPTC). The
method reported normalized values for each gene in a certain sample as
the ratio of the count of the speciﬁc gene to the total counts of all
endogenous genes within the GPS of the same sample.
2.6. SVM classiﬁcations and estimate of predictive performances
Themost suitable normalization strategy for GARDwas evaluated
by estimating predictive performances of support vector machine
(SVM) models (Cortes & Vapnik, 1995), using a leave-one-out
cross-validation (LOOCV) procedure. SVMs were compiled in R
statistical environment, using the additional package e1071
(Dimitriadou, Hornik, Leisch, Meyer, & Weingessel, 2011). In short,
SVM models, based on linear kernels and default settings, wererepeatedly trained on all but one sample, and the left out sample
was set aside to estimate model performance. The process was iter-
ated until all samples had been assigned a SVM decision value
(SVM DV). Decision values for all samples were collected and used
to generate a receiver operating characteristics (ROC) curve, and
the area under the curve (AUC) served as measure of model perfor-
mance (Lasko, Bhagwat, Zou, & Ohno-Machado, 2005). Calculations
and visualizations were performed in R statistical environment,
using the additional package ROCR (Sing, Sander, Beerenwinkel, &
Lengauer, 2005). The Predictive performance of GPS was estimated
using the independent test sets, as described in Johansson et al.
(2014). Brieﬂy, the SVM model described above was again trained
on samples in the training set, using GPS as variable input, and ap-
plied to classify samples in test sets. Prior to ﬁnal classiﬁcation of
samples in test sets, the SVM model was calibrated on internal
control samples in the corresponding benchmark set. During model
calibration, the trained SVM was applied to predict sensitizing
ividual replicate sample a SVM DV. Predictions were compared to
true sensitizing properties for each compound, and the accuracy
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classiﬁcation. The trained SVM was then again applied to predict
samples in test sets. SVM DVs for each sample in the test sets were
then scaled by subtracting the discrimination threshold, which max-
imized model performance for prediction of samples in the corre-
sponding benchmark set. Final classiﬁcation of a certain chemical
was then based on the median SVM DV value for the triplicate stim-
ulations; hence a speciﬁc compound was classiﬁed as a sensitizer if
the median output value of replicates N0. Accuracy, sensitivity and
selectivity of predictions were determined using cooper statistics
(Cooper, Saracci, & Cole, 1979). Principal component analysis (PCA)
plots and heatmaps were constructed in Qlucore Omics Explorer
3.2 (Qlucore AB, Lund, Sweden).
2.7. Predictive performances of alternative classiﬁcation models
The predictive performance of GPS was also estimated using the in-
dependent test sets on a selection of supervised machine learning algo-
rithms. Generation of binary predictive models, additional pre-
processing of data, model tuning and classiﬁcations were performed in
R statistical environment, using the caret package (Kuhn et al., 2016).
Prior to model construction, gene expression data for predictors within
GPS was centered round a mean value of zero, and scaled to a standard
deviation of one. Tuning parameters for each model was determined
using a resampling procedure of 10-fold cross-validation (repeated 15
times) on samples in the training set prior to prediction of samples in in-
dependent test sets. Predicted class probability values were collected
and used to generate a ROC curve, and the best performing model
from resampling results across tuning parameters was determined
based on highest ROC AUC value. For the KNNmodel, the optimal num-
ber of neighbors (k) was determined to 61. The partial least squares
(PLS) model was constructed using the additional package pls (Mevik
& Hovde Liland, 2015). The optimal number of components (ncomp)
to be used in the classiﬁcation model was determined to 3. The random
forest (RF) (Breiman, 2001)modelwas constructed using the additional
package randomForest (Liaw & Wiener, 2002). The number of trees
(ntrees) used in the ﬁnal model was set to 5000, and the optimal num-
ber of variables randomly sampled as candidates at each split (mtry)
was determined to 3. Additional parameters for each model were kept
at default settings. The process of training, calibration and ﬁnal classiﬁ-
cation of samples was performed as described for the SVM classiﬁca-
tions, using the class probability values generated by each model for
classiﬁcations. Calibrated class probabilities for individual samples of
each chemical were summarized in series of box andwhisker plots gen-
erated in R statistical environment, with the additional package ggplot2
(Wickham, 2009). For reproducibility of models based on stochastic
subsampling, the set.seed function within R was used.
3. Results
3.1. Evaluation of appropriate normalization strategies
To investigate the possibility to directly implement nCounter mea-
surements into current GARD protocols, we designed a custom
NanoString CodeSet to match targets in the GPS biomarker signature.
Following standardized protocols of GARD, reference chemicals in the
training set (Table 1) were used for stimulation of cells, and chemical-
ly-induced changes on transcriptional levels within the GPSwere inves-
tigated using the nCounter platform. Prior to data analysis, two different
strategies for normalization were evaluated. NanoString currently rec-
ommends a normalization strategy, which involves adjustment to a
set of stably expressed reference genes. Thus, the performance of a se-
lection of candidate reference genes (n = 24, Supplementary Table 2)
was ﬁrst evaluated using geNorm and BestFinder algorithms (Supple-
mentary Figure 1). The ﬁve most stable reference genes from
NormFinder rankings (GNB1, ABCF1 (3), ARF1MIR3620, SDHA andABCF1 (2)) were selected for normalization of data. As an alternative
to the reference normalization strategy, gene expression data was also
normalized using our in-house developed single sample normalization
method, called Counts per Total Counts (CPTC). In Fig. 1A and B, PCA
wasused to summarize gene expression data from the different normal-
ization strategies, using GPS as variable input. Expression proﬁles from
reference gene normalized data (Fig. 1A) and CPTC normalized data
(Fig. 1B) formed similar patterns, with a partial separation of sensitizers
and non-sensitizers along the ﬁrst PCA component. The formation of
separate clusters indicated that nCounter was able to reproduce the dif-
ferences in expression proﬁles between sensitizers and non-sensitizers
observed during microarray studies on the same reference set of
chemicals, regardless of normalization strategy. In Fig. 1C and D, the un-
supervised visualizations were supplemented with a supervised evalu-
ation of the predictive capacity of each normalization strategy, using a
SVM model in combination with a LOOCV procedure on samples in
the training set. As indicated in the ﬁgure, the predictive performance
of reference gene normalized data (Fig. 1C) and CPTC normalized data
(Fig. 1D) were identical. The high ROC AUC values (ROC AUC = 0.92)
obtained from each model indicated a potent ability of both strategies
to distinguish sensitizers from non-sensitizers, and conﬁrms the visual
ﬁndings of partly separated groups in the PCA plots. Considering logistic
beneﬁts of normalizing samples individually rather than in groups for
chemical testing using GARD, the single sample CPTC normalization
was used for all downstream analysis.
3.2. Calibrations of SVM classiﬁcation models for maximal predictive
performance
The ability of GPS to accurately classify unknown test compounds in
a model based on nCounter measurements was evaluated using test set
1 and test set 2 (Table 2). Compounds in the test sets were predicted
blindly and comprised novel stimulations, processed in separate
batches fromeach other and from the training set. Due to previously ob-
served issues when combining different batches of experiments, we in-
troduced the concept of including samples with known sensitizing
properties into each test set, so-called benchmark control samples.
The benchmark control samples included in test set 1 and 2 were re-
ferred to as benchmark set 1 and 2 (Table 2), respectively. In Fig. 2,
PCA was used to visually investigate possible shifts in transcriptional
levels between the training set and benchmark sets. Samples in the
training set were used to construct the PCA space, components were
frozen, and samples in benchmark set 1 (Fig. 2A) and benchmark set 2
(Fig. 2B)were plotted into the frozenmodel. As evident from the ﬁgure,
separation of sensitizers and non-sensitizers follows the ﬁrst PCA com-
ponent for samples in both training and benchmark sets. The unsuper-
vised PCA visualizations were veriﬁed using supervised SVM
classiﬁcations of benchmark samples. Results from SVM predictions
are illustrated in Fig. 2C. The cutoff threshold for maximum perfor-
mance for prediction of samples in benchmark set 1 was determined
to 1.01, and for benchmark set 2 to 0.23. Thus, SVM predictions indicate
that samples processed in both benchmark sets would require calibra-
tion prior to comparison to historical data, in order not to generate
false positive classiﬁcations.
3.3. SVM classiﬁcations and estimate of predictive performance using inde-
pendent test sets
Prior to supervised classiﬁcations of samples in test set 1 and 2, an
attempt was made to perform visual classiﬁcations. The PCA models
used for visualization of benchmark sets (Fig. 2), were applied also for
visualization of samples in independent test sets. In Fig. 3, samples in
test set 1 (Fig. 3A) and test set 2 (Fig. 3B), at the time blinded to the
model, were plotted into the frozen PCA space. Upon disclosure of
true identities of samples in test set 1 (Fig. 3C) and 2 (Fig. 3D), a separa-
tion along the ﬁrst PCA component was once again evident between
Fig. 1. Validation of predictive performances of various normalization strategies. Principal component analysis (PCA) was used to visualize all samples in the training set (n= 120) using
genes in GPS (n= 196) as variable input. The PCA space was constructed based on (A) reference gene normalized data, or (B) Count Per Total Count (CPTC) normalized data. Samples are
colored according to sensitizing properties (red= sensitizers, green=non-sensitizers), and a clear separation between the two groups can be observed along theﬁrst PCA component for
both normalization strategies. The predictive performance of a model constructed on either normalization strategywas validated using a SVM based LOOCV procedure. A SVMmodel was
trained on all but one sample in the training set, and the left out sample was used to validate the model. The process was repeated until all samples had been used for validation, and the
predictive performance of themodel was summarized using AUC ROC. The predictive performance of a model based on (C) reference gene normalized data, or (D) CPTC normalized data
was identical and estimated to 0.92.
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appeared to be well-calibrated, the transcriptional shift previously
observed during classiﬁcation of benchmark set 2, was evident also
among samples in test set 2. To verify visual classiﬁcations, the SVM
model used for prediction of benchmark sets was applied also for
prediction of samples in the test sets. However, prior to ﬁnal classiﬁca-
tions, the SVM DVs for each individual sample in the test sets were
adjusted against the cutoff threshold for maximum performance for
prediction of samples in corresponding benchmark set, to adjust for
batch to batch variations between training set and test sets. Calibrated
SVM DVs are reported in Supplementary Table 3, and further summa-
rized in combination with GPS expression proﬁles for each individual
sample in Fig. 4. In accordance with visual classiﬁcations, a clear dis-
crimination between sensitizers and non-sensitizers are observed in
test set 1 (Fig. 4A) and 2 (Fig. 4B), whichwas veriﬁed by ROCAUC values
of 0.93 and 0.91, respectively (data not shown). In general, themajority
of the sensitizers were assigned higher SVM decision values by the
model in comparison to non-sensitizers, which also are reﬂected by
observed differences in expression proﬁles between most compounds
within each group. GARD was able to classify the 29 compounds intest set 1 and 2 with an accuracy, sensitivity and speciﬁcity estimated
to 90%, 94% and 83%, indicating amodelwith good discriminating ability
and well calibrated cutoffs for decision making. Supplementary cooper
statistics for separate test set are summarized in Table 3.
3.4. Evaluation of alternative supervised machine learning algorithms for
classiﬁcation of samples in independent test sets
To determine if the predictive performance of GPS could be further
improved based on the high quality data produced on nCounter, we
evaluated a selection of well-described supervised machine learning al-
gorithms for classiﬁcation, and correlated their performance metrics to
SVM classiﬁcations. Since model parameters can affect predictive per-
formances, each model was optimized by iteratively evaluating avail-
able tuning parameters using cross-validation. Importantly, models
were only optimized based on samples in training data in order to pre-
vent overﬁtting. Optimized models were subsequently trained on sam-
ples in training set, calibrated to maximum performance based on
classiﬁcations of samples in benchmark sets, and applied to classify
samples in test sets. In Fig. 5, the calibrated class probabilities for each
Fig. 2. Calibration of the predictive model using benchmark controls. Unsupervised PCA
analysis was used to visually inspect benchmark control samples for batch effects. A
three-dimensional PCA space was constructed based on all samples in the training set
(n = 120), using genes in GPS (n = 196) as variable input, and samples were colored
according to sensitizing properties (sensitizer = red, non-sensitizer = green). Internal
control samples in (A) benchmark set 1 (n = 36), and (B) benchmark set 2 (n = 30)
were plotted into the PCA space constructed by samples in training set, without
contributing to PCA components. Control samples were colored according to sensitizing
properties in slightly darker colors than samples in the training set. (C) Visual effects
were conﬁrmed using a SVM model. The SVM was trained on samples in training set
and applied to predict sensitizing properties of samples in each benchmark set. The
accuracy of the SVM model was plotted as a function of SVM decision value cutoff
(benchmark set 1 = ﬁlled line, benchmark set 2 = dashed line).
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median values from triplicate stimulations, the accuracies of the PLS
model (Fig. 5A for test set 1, and Fig. 5B for test set 2), the KNN model
(Fig. 5C and D), and the RF model (Fig. 5E and F) for classiﬁcation of
samples in the independent test sets were estimated to 90%, 93% and100%, respectively. Additional cooper statistics for each model are sum-
marized in Table 4.
4. Conclusion
Extensive efforts have been invested in the development of mecha-
nistically relevant in vitro assays for prediction of chemical skin sensi-
tizers to replace current animal testing. However, to date few assays
have been formally validated and nonehas yet gained full regulatory ac-
ceptance to be used as a stand-alone assay (Dumont, Barroso, Matys,
Worth, & Casati, 2016). Several attempts have been made to combine
information from different assays, each targeting different immunolog-
ical key mechanisms in sensitization, into an ITS (Bauch et al., 2012;
Natsch et al., 2013). Ultimately, the success of such a strategywill be de-
pendent on the ability of the individual ITS components to provide accu-
rate and reliable data.
GARD is an in vitro assay for assessment of skin sensitization, ad-
dressing the DC activation step in the AOP for skin sensitization. In con-
trast to assays covering the same key event, such asU-SENS™ (Piroird et
al., 2015) and h-CLAT (Ashikaga et al., 2006; Nukada et al., 2011), which
rely on single or fewmarkers for classiﬁcation, the GARD assay is based
on measurements of a large set of genes within a genomic biomarker
signature, comprising genes involved in immunological relevant path-
ways associated with skin sensitization. The high informational content
enables mechanism-of-action based decisions, well-correlated to cur-
rent recommendations within toxicity testing (NRC National Research
Council, 2007). In this study, we describe modiﬁcations to the GARD
workﬂow to better meet future industrial and regulatory demands on
reliability, protocol robustness, sample throughput and assay costs.
We transferred gene expression measurements from transcriptome-
wide microarrays to themore focused NanoString nCounter, measuring
only transcripts in the biomarker signature. The platform transfer was
validated by generating novel cellular stimulations and evaluating the
predictive performance of the GARD assay based on nCounter measure-
ments. A total of 29 compounds were selected as independent test
chemicals to estimate model performance. Using internal control sam-
ples, so-called benchmarks for calibration of batch effects, compounds
in test sets could be classiﬁed by the SVM with a sensitivity, speciﬁcity
and accuracy of 94%, 83% and 90%, reaching similar predictive metrics
as the model based on microarray measurements. Of the 16 previously
correctly classiﬁed compounds, 14 (88%) were correctly predicted by
the SVMmodel based on nCountermeasurements in this study, indicat-
ing good agreement between platforms. In addition to the predictive
performance described for the overall SVM classiﬁcations, we also
show that the predictive performance of the assay could be improved
when applying alternative machine learning models for classiﬁcation.
Changing to a RFmodel, all of the testing compounds could be accurate-
ly assigned to the right class, reaching an accuracy of 100%. Additionally,
on the level of individual replicates, the RF model did not have a single
misclassiﬁcation, indicating robustness in predictions. Since limited or
insufﬁcient human datawas available for most of the chemicals, predic-
tive performances were calculated in relation to LLNA. Exceptions were
made for compounds known as false predictions in LLNA, as indicated in
Table 2, and for the two chemicals DMTBS and DETBS, where LLNA data
was missing. These two chemicals are rubber allergens present in cer-
tain disposable rubber gloves, and show positive reactions in human
patch testing (Hansson, Ponten, Svedman, & Bergendorff, 2014). Based
on a dataset of 139 chemicals, h-CLAT recently reported an accuracy of
78% (Takenouchi et al., 2015). KeratinoSens and DPRA reported similar
accuracies (77% and 80% respectively) when challenged with 145
chemicals (Natsch et al., 2013). In this respect, the GARD assay should
be considered as highly competitive.
Hazard classiﬁcation is a ﬁrst step towards a more complete toxico-
logical safety assessment of chemicals,whichwould involve an estimate
also of relative potency. Similar to binary classiﬁcations, a full estimate
of potency is anticipated to require a combination of assays targeting
Fig. 3. Visual classiﬁcations of samples in independent test sets. A three-dimensional PCA spacewas constructed by samples in the training set (n= 120), based on expression data of the
196 genes in GPS. Samples were colored according to sensitizing properties (sensitizer= red, non-sensitizer= green). Samples in (A) test set 1 (n=60) and (B) test set 2 (n= 27)were
plotted into the space generated by the training set, without affecting PCA components. Samples in test sets were colored in grey to highlight that they were previously unseen by the
model, and not contributed to the representation of the PCA space. True identities of samples in (C) test set 1 and in (D) test set 2 were revealed and colored according to sensitizing
properties (sensitizer = dark red, non-sensitizer = dark green), and the training set was removed to facilitate interpretation.
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are suchmethods based onmachine learning algorithms (Tsujita-Inoue,
Atobe, Hirota, Ashikaga, & Kouzuki, 2015; Tsujita-Inoue et al., 2014),
and BayesianNetworks (Jaworska et al., 2015). Themachine learning al-
gorithms used in GARD effectively translate the genomic biomarker sig-
nature proﬁles of each compound into a continuous scale of predictions.
It would thus be tempting to evaluate GARD predictions within an ITS
for skin sensitizing potency, as the ones suggested above, to elucidate
if GARD is able to provide also quantitative assessments.
To improve reliability and reproducibility in predictions, we intro-
duced a novel method to calibrate GARD predictions prior to classiﬁca-
tion of unknown testing compounds. Since classiﬁcation of unknown
compounds relies on comparison to historical reference data in the
training set, test samples will be processed at a different time point in
comparison to training samples, thus risking the introduction of techni-
cal variations, and complicate predictions. Visual inspections of samples
in test sets using a PCA frozen on samples in training set revealed a clear
discrimination between sensitizers and non-sensitizers, supporting ourprevious claims that the GPS biomarker signature contains genes rele-
vant to the sensitization process. However, discrimination does not in-
trinsically mean a good calibration, and we observed slight shifts in
transcriptional proﬁles between samples processed in the various
batches. To reduce such impacts of batch-to-batch variations, and to
avoid having to rerun a complete training set together with new sam-
ples, we included a panel of carefully selected samples from the training
set, so-called benchmarks, into each test set. These sampleswith known
expected outcomes were used to adjust the cutoff of the classiﬁcation
model to maximize performance prior to evaluating unknown testing
compounds. A similar exercise for calibration of SVM outputs have
been described by Jiang, Menon, Wang, Kim, & Ohno-Machado (2012).
Importantly, the position of the cutoff was only determined based on
the benchmark samples, the test compounds were still completely un-
known to the model during calibration. However, it is reasonable to as-
sume that such a cutoff will be applicable also to unknown samples
processed in same batch. Indeed, the calibrated cutoff improved the ac-
curacy from 79% to 90%, and signiﬁcantly reduced the number of false
Fig. 4. SVM classiﬁcations of samples in independent test sets. A SVMmodel trained on all samples in the training set (n= 120)was applied to predict sensitizing properties of individual
replicate samples in (A) test set 1 (n= 60) and (B) test set 2 (n=27). Prior to ﬁnal classiﬁcation, the SVMDVs for each replicate sample in test sets were ﬁrst calibrated against the cutoff
for maximum accuracy obtained during classiﬁcation of internal control samples in the corresponding benchmark set (test set 1 = 1.01, test set 2 = 0.23). SVM DVs were sorted in
decreasing order from highest to lowest, and colored according to true sensitizing properties (sensitizer = dark red, non-sensitizer = dark green). Dashed lines indicate the cutoff
threshold used for classiﬁcation by the model (SVM DVs N 0 = sensitizer, SVM DVs b 0 = non-sensitizer). On individual replicate level, a total of 87% (76/87) of samples were
correctly classiﬁed by the model. Heatmaps illustrate expression proﬁles of transcripts within GPS for each sample in independent test sets.
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changing the cutoff does not change the model or the input variables
in the GPS, but it allows for adjusting technical variations in each
batch in relation to the biological information in each test set. In addi-
tion, since accuracy is a trade-off between sensitivity and speciﬁcity,
the model can similarly be calibrated to reach a higher sensitivity,
which can be of importance to avoid false negative predictions.
Further important actions to facilitate the current workﬂow of GARD
were taken during initial normalization steps. In GARD, novel testing sub-
stances may arrive serially in batches, and each sample needs to be com-
pared to historical reference samples. Thus, having to rely on a strategy
that requires samples to be processed simultaneously during normaliza-
tion would be highly impractical, since historical data would need to be
renormalized each time new samples arrives. To address the need for a
single sample normalization strategy, we evaluated an alternativeTable 3
Cooper statistics summarizing predictions on individual test sets using the SVMmodel for
classiﬁcation.
Correctly classiﬁed compounds Test set 1 Test set 2 Total
Sensitizers 10/11 6/6 16/17
Sensitivity (%) 91% 100% 94%
Non-sensitizers 8/9 2/3 10/12
Speciﬁcity (%) 89% 67% 83%
Total 18/20 8/9 26/29
Accuracy (%) 90% 89% 90%method for correction of sample variability, based on Counts per Total
Counts (CPTC). The strategy is a modiﬁcation of Total Count Normaliza-
tion in RNA-seq (Dillies et al., 2013) and is used to normalize differences
in RNA inputs. The suggested normalization strategy performed similar to
reference normalization on the samples in the training set, andperformed
well during predictions of test chemicals.
Finally, the microarray platform will continue to be an important
and integrated part of GARD assay development. Measuring complete
transcriptomes of cells provides important information in order to
study cellular signaling pathways and may be used to extract informa-
tion relevant to sensitizing potency, as suggested in Albrekt,
Johansson, Borje, Borrebaeck, & Lindstedt (2014). The platform has
also proven useful for extending the applicability domain of GARD to
cover prediction of additional endpoints through identiﬁcation of sepa-
rate biomarker signatures, such as chemical respiratory sensitizers
(Forreryd, Johansson, Albrekt, Borrebaeck, & Lindstedt, 2015), and re-
cently also for skin sensitizing potency (manuscript under preparation).
In conclusion, we here present a streamlined GARD workﬂow to ad-
vance from global biomarker discovery into a reliable and resource-ef-
fective format based on the NanoString nCounter platform. When
challenged with 29 test compounds, the GARD assay correctly classiﬁed
90%based on SVMpredictions, validating thepredictive relevance of the
GPS biomarker signature on an alternative platform. When combining
the high quality nCounter data with a powerful RF model for classiﬁca-
tion, we demonstrated that all 29 test compounds could be accurately
predicted. We argue that GARD is well-adapted for routine testing,
and that the assay is ready for implementation into an ITS to reﬂect
the DC activation step in the AOP for skin sensitization.
Fig. 5.Classiﬁcations of samples in independent test sets using various supervisedmachine learningmodels.Machine learningmodelswere trained on all samples in training set (n=120)
and applied to predict each individual sample in test sets. Prior to ﬁnal classiﬁcations, the prediction output from each model, the class probability votes, was ﬁrst calibrated against the
cutoff formaximumaccuracy obtained during classiﬁcation of internal control samples in the corresponding benchmark set. Calibrated class probability votes for triplicate samples of each
chemical were summarized in series of box andwhisker plots for the (A) partial least squares (PLS)model on test set 1 and (B) test set 2, the (C) K-nearest neighbor (KNN)model on test
set 1 and (D) test set 2, and the (E) random forest (RF)model on test set 1 and (F) test set 2. Sampleswere colored based on classiﬁcations provided by eachmodel (sensitizer= dark red,
non-sensitizer=dark green). The horizontal dashed line in each subplot represents the cutoff threshold usedbymodels for classiﬁcation as sensitizers (class probability votes N0), or non-
sensitizers (class probability votes b0), and the vertical dashed line marks the separation between true sensitizers and true non-sensitizers (left = sensitizers, right = non-sensitizers).
Using median value of replicates for classiﬁcation of a certain chemical, the accuracy of the PLS, KNN and the RF models was estimated to 90%, 93% and 100%, respectively. TP = true
positive, FP = false positive, TN = true negative, FN = false negative.
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